Upcoming events

WMIC 2014

09/17/2014 to 09/21/2014
Seoul, Korea

Imaging in 2020

09/21/2014 to 09/25/2014
Jackson Hole, WY

Monoclonal antibodies (mAbs) are a proven strategy for generating incredibly selective targeting agents. ImaginAb harnesses the specificity of mAbs to engineer small, highly targeted proteins for imaging important molecular targets with Positron Emission Tomography (PET). ImaginAb’s technology produces actionable data that increases diagnostic precision, improves treatment decisions in the clinical setting, and enhances the development of new therapeutic drugs.

ImaginAb has utilized this strategy to generate a rich pipeline of in vivo imaging agents in oncology and immunology, both as stand-alone clinical products and in partnership with select biopharmaceutical companies.